Status:
TERMINATED
Influenza Vaccine Post Allogeneic Transplant
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Conditions:
Hematopoietic Stem Cell Transplant
Hematologic Malignancy
Eligibility:
All Genders
6+ years
Phase:
NA
Brief Summary
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive o...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient Population
- HSCT recipients who are greater than 60 days post transplant.
- Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant
- Show neutrophil recovery, platelet count \> 50,000/mm3 (may be transfused), no known disease relapse
- No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
- No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months
- Controls:
- Age 18 to 50 years
- No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
- No flu vaccine in previous 4 months
Exclusion
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01215981
Start Date
September 1 2010
End Date
June 1 2011
Last Update
December 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States, 55455